Outsourcing

Pharmaceutical Outsourcing Present and Future

Contract service providers must step up their game to stay competitive in increasingly complex bio/pharma market.

Navigating the Preclinical CRO Outsourcing Process

The need for preclinical testing expertise is growing as molecular complexity increases.

A Closer Look at Affinity Ligands

A look at the newest innovations offers a deeper understanding of affinity ligands and their role in the future of downstream processing.

Catalent, Arcturus Therapeutics Sign Vaccine Deal

May 05, 2020

Catalent will manufacture a mRNA-based COVID-19 vaccine for clinical trials and potential commercialization.

Fujifilm Diosynth Biotechnologies Reserves Capacity for COVID-19 Therapeutics Accelerator

May 04, 2020

Fujifilm allocates production volumes for COVID-19 treatments in 2021 at its Denmark facility.

Ensuring Smooth Tech Transfer of Bioprocesses to Outsourcing Partners

May 02, 2020

Experience, communication, collaboration, transparency, planning, and prioritization contribute to success.

Lonza, Moderna Form Global Collaboration to Manufacture Moderna’s COVID-19 Vaccine

May 01, 2020

The goal of the collaboration is to manufacture up to one billion does per year of mRNA-1273, Moderna’s vaccine against the novel coronavirus.

Catalent Announces Cell & Gene Therapy Leaders

May 01, 2020

Manja Boerman tapped as president of Cell & Gene Therapy for Catalent with retirement of Pete Buzy.

Private Equity Firm Invests in Tjoapack

April 30, 2020

Private equity firm, Ampersand Capital Partners, has made a majority investment into contract packaging organization (CPO), Tjoapack.

Wavelength Pharmaceuticals Expands Supplies of Drug Ingredients for Managing COVID-19 and Adds API CDMO Services

April 23, 2020

Wavelength Pharmaceuticals expanded production of APIs for certain pharmaceutical products needed to manage respiratory critical care patients in the COVID-19 pandemic.

Catalent Expands Biologics Packaging Capacity

April 23, 2020

Catalent Biologics increased capacity at its Bloomington, IN Facility.

MilliporeSigma Adds Viral Vector and Gene Therapy Capacity

April 21, 2020

The company will build an additional commercial-scale, contract manufacturing facility for viral vectors and gene therapies near its existing site in Carlsbad, CA.

FDA Publishes Temporary Policy on Compounding of Drugs

April 16, 2020

The guidance document describes the agency’s temporary policy for the compounding of drugs during the COVID-19 pandemic.